Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

ALBANY — Democratic Assemblyman Edward Gibbs, who represents parts of east Harlem, violated the house’s policy by making sexually explicit remarks on the Assembly floor, according to findings ...

Cathie Wood’s ARK ETF published their daily trades for Friday, December 19th, 2025, showcasing significant activity in several key stocks. Leading the trades was a substantial sale of 23,110 shares of ...

Jeremy Renner is firing back after Chinese filmmaker Yi Zhou accused him of sending explicit images and making deportation threats — allegations the actor is calling "completely false." Zhou, who said ...

Jeremy Renner is denying the allegations made against him by director Yi Zhou after she accused the actor of sending her explicit images and then threatening to “call ICE” on her after their ...

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.

Parents may want to press pause before blaring Taylor Swift’s new album around young listeners. Eight out of the twelve songs on "The Life of a Showgirl" are labeled explicit, marking the most Swift ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.52, marking a +2.41% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.54% ...

Before market open, Recursion disclosed in a tersely worded regulatory filing with the Securities and Exchange Commission (SEC) that it was taking a series of measures to streamline its operations.